The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China

• Main Authors: Zhanjing Dai (Author), Jiayi Xu (Author), Feng Chang (Author), Wanxin Zhou (Author), Ting Ren (Author), Jiaxin Qiu (Author), Yun Lu (Author), Yuqiong Lu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundIruplinalkib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with efficacy in patients with ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC), which is independently developed by a Chinese pharmaceutical company. This stud...